Research presented at a European conference found that wearers of cardiac devices should keep a safe distance from smartphones.
A strategic device company, a former Medtronic president and an award-winning Stanford doctor are among the financiers of Silicon Valley's EBR Systems' attempt to commercialize the first leadless pacemaker implanted in the heart's left ventricle. Along with VCs like Split Rock Partners and SV Life Sciences, the group contributed $20 million toward the groundbreaking effort.
Boston Scientific advised physicians about a particular pacemaker in 2005--but then declined to pay the bills for those surgeries that it subsequently received from German health insurers. An EU court ruled on March 5 that the company is liable for those costs, according to Reuters.
St. Jude Medical has gained approval for a quadripolar cardiac resynchronization therapy pacemaker that for the first time incorporates its MultiPoint Pacing technology that's been shown to be better for patients who don't respond to traditional biventrical pacing.
Boston Scientific owes $309 million in royalties and other expenses to Mirowski Family Ventures, associated with the deceased Dr. Michel Mirowski, principal inventor of the the pacemaker, said a jury in Maryland's Montgomery County Circuit Court yesterday.
Medtronic snagged FDA approval for its next-generation cardiac resynchronization therapy (CRT) pacemaker in patients with heart failure, expanding its cardiovascular portfolio and advancing its proprietary technology for heart rhythm therapy.
Engineering students at Purdue University have come up with what they say is a simple, cost-effective tool cardiac surgeons can use to test whether pacemaker leads have been securely anchored to heart tissue.
Australian regulators have issued a "hazard alert" warning that a manufacturing snafu may cause a version of Medtronic's Consulta pacemaker to take in bodily fluid and then malfunction. But another model has also displayed problems; the company says it has recalled affected batches of both, and also notified surgeons.
Nanostim says its tiny wireless cardiac pacemaker has shown some success in its first three human patients, early signs that the potentially disruptive technology has legs. And the company's advance, presented this week at the Heart Rhythm Society meeting in Denver, may give it the lead over larger medical device rivals trying to come up with something similar.
Medtronic gained FDA approval for what will become its second MRI-friendly pacer in the United States, and only the second device of its kind to gain a regulatory nod here.